

**Director's Report on Developmental Consultation and Recommendations**

**Date of Visit:** 16-04-2025

**Child's Name:** Callan-Noel Jennings

**Date of Birth:** 04-05-2021

**Age:** 3

**Gender:** Male

**Overview:**

Callan-Noel Jennings was **not fully assessed** during this visit. Instead, the session involved an **in-depth consultation** provided to the parents, focusing on the **review and interpretation of previous test results and reports**. The data suggests possible **genetic deletions, variants, and mitochondrial abnormalities**. However, there are **notable inconsistencies and contradictions** among the findings from prior evaluations. As such, a full reassessment and further analysis are necessary to confirm the underlying causes and to ensure the **validity of previous interpretations**.

A comprehensive assessment using **advanced diagnostic technologies** is strongly recommended to uncover the contributing factors and establish a reliable baseline for therapeutic planning.

**Recommended Plan:**

**1. Development Protocol for Information Processing Delays:**

- Continue with a structured **intervention plan for 4 months**.
- Schedule a **full in-person reassessment** after this period.
- Reevaluate and update the child's **developmental baseline**.
- Complete a full cycle of therapeutic sessions during the period.

**2. Recommended Analysis (Canada – Neurazon):**


- **Functional Urine Analysis**
  - Focus: Evaluate **mitochondrial function and energy metabolism**.
  - Sample: **Urine**
  - Turnaround Time: **3 months (business days)**.
- **Precision Health Analysis (Whole Genome Study)**
  - Focus: Comprehensive evaluation of **genetic variants, potential deletions**, and root causes.
  - Sample: **Saliva**
  - Turnaround Time: **4 months (business days)**.

### 3. Recommended Therapy:

- Initiate **Neuroplasticity Rehabilitation Therapy** at a frequency of **2–3 sessions per week**.
- Therapy should focus on enhancing **cognitive flexibility**, **neural development**, and **functional recovery**.


### Conclusion:

This report serves as a **consultation summary** and outlines a preliminary plan for further evaluation and intervention. The current findings are not sufficient to form a final developmental diagnosis. With appropriate follow-up analysis and therapy, Callan-Noel Jennings has the potential for meaningful progress. All recommendations are based on internationally recognized protocols and the clinical tools developed by **Neurazon (Canada)**.



**EICADD**

**Signature**  
EICADD Center Director



Dr. Nouraldin Al-Dani